About DeFi Development Corp. BOCA RATON, FL, May 28, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the "Company" or "DeFi Dev Corp."), the first public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced its adoption of liquid staking token ("LST") technology. As part of this initiative, DeFi Dev Corp. will invest part of its SOL treasury in dfdvSOL, an LST representing stake delegated to DeFi Dev Corp. validators and built with protocol infras ...

Core Viewpoint - Annaly Capital Management (NLY) presents a more attractive investment opportunity compared to Arbor Realty Trust, Inc. (ABR) due to its stronger liquidity, sustainable dividend, and positive financial outlook, while ABR faces significant risks and challenges [1][19]. Group 1: Annaly Capital Management (NLY) - NLY is focused on improving liquidity and reducing leverage, with total assets available for financing amounting to $7.5 billion, including $4.7 billion in cash and unencumbered Agency mortgage-backed securities (MBS) [2]. - The company has a monthly dividend yield of 14.9% and a payout ratio of 101%, with a recent cash dividend increase of 7.7% to 70 cents per share, indicating confidence in cash flow and growth prospects [3]. - NLY's investment strategy includes traditional Agency MBSs for downside protection and investments in non-agency and credit-focused asset classes to enhance returns, supported by a scaled mortgage servicing rights (MSR) platform [4]. - As of March 31, 2025, NLY's investment portfolio totaled $84.9 billion, and the company expects book value improvement as mortgage rates decline, which will enhance net interest spread and overall yield [5][6]. - The Zacks Consensus Estimate for NLY's 2025 and 2026 sales indicates year-over-year increases of 492.8% and 13.2%, respectively, with earnings expected to rise by 6.3% and 1.4% in the same periods [13]. Group 2: Arbor Realty Trust, Inc. (ABR) - ABR focuses on originating and servicing loans for multi-family, single-family, and commercial real estate assets, with expectations of improved mortgage originations as housing affordability challenges decline [7]. - The current dividend yield for ABR is 12.66%, but the company recently reduced its dividend by 30.3% to 30 cents per share, reflecting concerns over its weak liquidity position, which includes cash and cash equivalents of $508 million against long-term debt of $4.8 billion [8]. - ABR has significant exposure to multi-family loans, with seven non-performing loans totaling $196.7 million foreclosed in the first quarter of 2025, indicating credit risk [9]. - The Zacks Consensus Estimate for ABR's 2025 sales suggests a year-over-year decline of 17.9%, with earnings expected to fall by 32.2% in the same year, although a slight recovery is anticipated in 2026 [17].

Amendment to Euronext’s liquidity contract Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 27 May 2025 – Euronext N.V. today signed an amendment to the liquidity contract entered into with Rothschild Martin Maurel on 7 February 2018, in accordance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014, Commission Delegated Regulation (EU) 2016/908 of 26 February 2016, Articles L. 225-209 et seq. of the French Commercial Code, AMF Decis ...

Group 1 - The Republic of Iceland repurchased EUR 203.7 million in nominal value of its outstanding 0.625% Eurobonds due 2026, which is over 40% of the original EUR 500 million issue [1] - The buyback was executed at a price of 98.81%, amounting to approximately ISK 29 billion [1] - The tender offer was launched on May 19, 2025, and closed on May 23, 2025 [1] Group 2 - This transaction is part of the Treasury's liquidity and debt management strategy, aimed at reducing near-term refinancing risk [2] - The buyback improves the maturity profile of the Government's debt portfolio [2] - The buyback was financed from proceeds of a new EUR 750 million Eurobond issued earlier in the week [2]

Group 1 - Kering has issued a single-tranche bond amounting to EUR 750 million with a maturity of 4.5 years and a coupon rate of 3.125% [1] - The bond issue is part of Kering's active liquidity management strategy, aimed at enhancing financial flexibility [1] - The successful bond issue reflects strong market confidence in Kering's credit quality, supported by a long-term rating of 'BBB+' from Standard & Poor's [1] Group 2 - Kering is a global luxury group that includes renowned brands such as Gucci, Saint Laurent, and Bottega Veneta, focusing on ready-to-wear, leather goods, jewelry, and beauty products [2] - In 2024, Kering employed 47,000 people and generated revenue of EUR 17.2 billion, highlighting its significant market presence [2]

Prophase Labs (PRPH) Q1 2025 Earnings Call May 20, 2025 10:00 AM ET Company Participants Noella Alexander-Young - Media Relations Coordinator & Virtual Events ModeratorTed Karkus - Chairman & CEO Noella Alexander-Young Hello, and good morning, everyone. Welcome to today's presentation. My name is Noella Alexander Young, virtual event moderator here at Renmark Financial Communications. On behalf of our team, we want to thank everyone for joining us today for Prophase Labs First Quarter twenty twenty five Res ...

Financial Data and Key Metrics Changes - The company reported a significant increase in shareholders' equity, which roughly doubled from approximately $7 million to over $15 million following the sale of a manufacturing facility [16][34][92] - The company is currently operating at breakeven for its Nebula Genomics division, which is expected to generate substantial cash flow in the future [60][89] Business Line Data and Key Metrics Changes - The b smart esophageal cancer test is anticipated to have a market potential of $7 to $14 billion, with the company expecting to receive reimbursement of $1,000 to $2,000 per test [46][47] - DNA Complete is generating around $5 million in annual revenues, with potential to reach $10 million with increased marketing efforts [93] Market Data and Key Metrics Changes - The company is exploring strategic alternatives for Nebula Genomics and DNA Complete, aiming to clean up its capital structure and reduce pressure on the stock price [54] - The company has a large genomic dataset of 16 petabytes, which is one of the largest in the world, enhancing its market position [58] Company Strategy and Development Direction - The company plans to focus on debt financing rather than issuing shares, aiming to maintain shareholder value while preparing for upcoming liquidity events [22][102] - The management is committed to a methodical approach to commercialization of the b smart esophageal cancer test, leveraging existing sales networks rather than building a new sales force [84] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in collecting approximately $20 million in uncollected accounts receivable, with expectations that actual collections could exceed this amount [106] - The company anticipates significant cash inflows in the second half of the year, driven by collections and the potential sale of Nebula Genomics [99][104] Other Important Information - The company has deferred a significant portion of executive compensation until liquidity events occur, demonstrating alignment with shareholder interests [25] - The company is actively working on legal matters with Crown Medical to recover underpaid reimbursements from insurance companies, which could lead to additional cash inflows [70][73] Q&A Session Summary Question: What is a realistic timeline for the commercialization of BSmart? - The first patient testing is expected to occur later this year, but commercialization will likely be a multiyear process [81] Question: What vaccines or illnesses are being worked on? - The company is not currently working on any vaccines and is focusing on the b smart esophageal cancer test and dietary supplements [88] Question: What steps are being taken to meet Nasdaq compliance? - The company has filed for an extension and is confident it will receive it, as it meets all other qualifications [90][91] Question: Has the DNA Complete division started generating revenues? - DNA Complete is generating around $5 million annually, with potential for growth through increased marketing [93] Question: Are we still looking at June/July for COVID testing payments? - The company is optimistic about receiving payments in June, with significant capital expected to flow in the second half of the year [96][99] Question: Have you accessed the line of credit from the global private equity group? - A small amount of capital has been taken in, and the company is exploring additional debt financing options [102] Question: What milestone items should shareholders be aware of for the balance of 2025? - Key milestones include the development of the esophageal cancer test and the rollout of Equivira, with a focus on maintaining cash reserves [104]

Core Viewpoint - The article discusses the advancements in liquid cooling technology for data centers, particularly highlighting Supermicro's new DLC-2 technology and its implications for energy efficiency and operational costs in the context of rising AI computing demands [2][5][9]. Group 1: Supermicro and DLC-2 Technology - Supermicro announced the launch of its next-generation DLC-2 technology, which has led to a fourfold revenue increase over the past three years, driven by the maturity of liquid cooling technology [2]. - The new data center construction modular solution (DCBBS) integrates the DLC-2 technology, achieving a 40% improvement in energy and water savings, a heat capture rate of 98%, and a noise level as low as 50db, while also reducing capital expenditures by up to 20% [2][9]. - Supermicro's stock has experienced significant volatility, with a 300% increase in 2023 due to AI demand, followed by an 80% decline in 2024 due to financial reporting delays and governance issues [7][12]. Group 2: AI Computing Power and Market Trends - NVIDIA's CEO Jensen Huang emphasized the critical role of computing power in AI development, noting that AI computing performance improves by a factor of one million every decade [4]. - The IDC report predicts that China's AI computing power market will reach $25.9 billion by 2025, growing 36.2% from 2024, while total energy consumption in Chinese data centers is expected to exceed 400 billion kWh, accounting for over 4% of total national consumption [4]. Group 3: Liquid Cooling Technology Overview - Liquid cooling technology is categorized into non-contact and contact types, with non-contact cooling being the most widely used due to its maturity [5]. - The average energy consumption for cooling systems in air-cooled data centers exceeds 50%, with higher ratios in AI computing centers [5]. - The emergence of high-density computing scenarios has led to the development of new immersion cooling solutions, which are expected to see widespread adoption as server power densities increase [5][6]. Group 4: Financial Performance and Future Outlook - MiaoSuan Technology, founded in 2023, aims for a revenue target of 300 million yuan in 2025, leveraging its immersion cooling technology [6][7]. - Supermicro's recent partnership with DataVolt in Saudi Arabia indicates ongoing interest in high-performance computing solutions despite past financial challenges [7]. - The operational efficiency of liquid cooling systems can lower Power Usage Effectiveness (PUE) to as low as 1.15, with potential for further reductions in specific areas [9].

固收 降准后的资金紧怎么看？20250519 摘要 • 近期债市整体偏震荡，受存款调降预期影响，收益率有所下行。市场对存 款利率调降幅度有期待，但预计不会超过贷款基点调降幅度。短期内，债 市可能维持震荡格局。 • 资金面仍然乐观，宽松存在超预期可能。即使短期波动或短端下行空间不 足，短端收益率仍有下降空间，取决于资金松动和价格指数进一步下行。 对收益率曲线平坦化后的走势更有确定性。 • 预计央行流动性投放将保持稳定宽松态势，双降之后央行流动性投放会达 到一个小规模高峰，包括结构性货币政策超额投放以及未来可能的 PSL 投 放，将使价格方向和预期偏向宽松。 • 降准实际落地后出现收紧现象，是由于银行按照 10 天或旬度进行平均法 考核，在新的降准维持期开启时需要补充超额准备金，导致暂时性的收紧。 需从时间点和幅度角度理解。 • 降准公告发布后，机构可以提前使用部分超额准备金，资金宽松效应提前 显现。不必担心降准落地后资金反而收紧，因为前期已经透支了部分宽松 效应。历史上降准实施落地后的两周内，资金价格呈现稳定或边际下行趋 势。 Q&A 最近债市的整体行情如何，主要受到哪些因素影响？ 最近债市整体处于波动状态。上 ...

Group 1 - The article discusses the positions of various analysts regarding specific stocks, indicating that Anand Chokkavelu, Karl Thiel, and Keith Speights do not hold any positions in the mentioned stocks [1] - The Motley Fool has positions in and recommends Guardant Health, highlighting its investment interest in this company [1]